Ikezaki S, Nishikawa A, Furukawa F, Tanakamura Z, Kim H C, Mori H, Takahashi M
Division of Pathology, National Institute of Health Sciences, Kamiyoga, Setagaya-ku, Tokyo.
Cancer Res. 1996 Jun 15;56(12):2767-70.
The modifying effects of 24R,25-dihydroxyvitamin D3 [24R,25(OH)2D3], a vitamin D3 derivative, on glandular stomach carcinogenesis were investigated in male Wistar rats by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and sodium chloride exposure during the postinitiation phase. A total of 130 male 6-week-old rats was divided into five groups. Groups 1-3 (consisting of 30 rats/group) were given MNNG in drinking water at a concentration of 100 ppm and were simultaneously fed a diet supplemented with 10% NaCl for 8 weeks. They were fed a diet containing either 5.0 ppm (group 1) or 2.5 ppm (group 2) 24R,25(OH)2D3 or were kept on the basal diet alone (group 3) for the following 57 weeks. Rats in groups 4 and 5 were given 24R,25(OH)2D3, as were animals in groups 1 and 3, but did not receive the MNNG + NaCl treatment. The total incidence of combined atypical hyperplasias and adenocarcinomas in the glandular stomachs was significantly lower in group 1 (24%) than in group 3 (70%; P < 0.01). The mean numbers of atypical hyperplasias or adenocarcinomas of the glandular stomachs in groups 1 (0.31) and 2 (0.66) were also significantly decreased (P < 0.01 and P < 0.05, respectively) as compared to the group 3 value (1.21). Thus, the development of cancerous and precancerous lesions in the glandular stomach was decreased by exposure to 24R,25(OH)2D3 in a dose-dependent manner. Urinary calcium levels were increased by this vitamin D3 derivative (in line with the applied dose) when assayed at 10, 30, and 62 weeks, regardless of the MNNG + NaCl treatment The present results clearly indicate that 24,25(OH)2D3 exerts chemopreventive effects, possibly by influencing calcium pharmacodynamics, when given during the postinitiation phase of glandular stomach carcinogenesis in rats.
通过在启动后阶段用N-甲基-N'-硝基-N-亚硝基胍(MNNG)和氯化钠处理雄性Wistar大鼠,研究了维生素D3衍生物24R,25-二羟基维生素D3 [24R,25(OH)2D3]对腺胃癌发生的修饰作用。总共130只6周龄雄性大鼠被分为五组。第1-3组(每组30只大鼠)饮用浓度为100 ppm的MNNG水溶液,同时喂食添加10%氯化钠的饲料,持续8周。在接下来的57周里,它们分别喂食含有5.0 ppm(第1组)或2.5 ppm(第2组)24R,25(OH)2D3的饲料,或者仅喂食基础饲料(第3组)。第4组和第5组的大鼠与第1组和第3组的大鼠一样给予24R,25(OH)2D3,但未接受MNNG + NaCl处理。第1组腺胃中合并的非典型增生和腺癌的总发生率(24%)显著低于第3组(70%;P < 0.01)。与第3组的值(1.21)相比,第1组(0.31)和第2组(0.66)腺胃中非典型增生或腺癌的平均数也显著降低(分别为P < 0.01和P < 0.05)。因此,腺胃中癌性和癌前病变的发展因暴露于24R,25(OH)2D3而呈剂量依赖性降低。在第10、30和62周检测时,无论是否接受MNNG + NaCl处理,这种维生素D3衍生物都会使尿钙水平升高(与应用剂量一致)。目前的结果清楚地表明,在大鼠腺胃癌发生的启动后阶段给予24,25(OH)2D3可能通过影响钙的药效学发挥化学预防作用。